~~<i id='BA0ACFD4ED'><strike id='BA0ACFD4ED'><tt id='BA0ACFD4ED'><pre id='BA0ACFD4ED'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：focus 2025-09-28 17:06:48 Page View：75169

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bill would stop addiction treatment from triggering child abuse inquiry
Next article： Peter Hotez and the public health issue of online harassment

explore

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

Gilgo Beach: Police identify another victim in serial killing investigation

9:19KarenVergatainaphotoSuffolkCountypolicedisplayedatapressconference,Aug.4,2023,toannouncethatGilg

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

What Mike Pence has said that could be used in a Donald Trump trial

1:11RepublicanpresidentialcandidateandformerVicePresidentMikePencespeakswiththemediaduringastopatthe